Clinical heterogeneity in dysferlinopathy
- PMID: 12132520
- DOI: 10.2169/internalmedicine.41.532
Clinical heterogeneity in dysferlinopathy
Abstract
Objective: To clarify the clinical heterogeneity and genotype-phenotype correlation in dysferlinopathy.
Methods: We evaluated clinical parameters of 74 dysferlinopathy patients with known dysferlin gene mutations who were previously reported in the literature.
Results: The age at onset varied from 12 to 59 years (mean 21.7 years). Based on the initial distribution of muscle involvement, clinical phenotypes were divided into four subtypes: limb-girdle type, Miyoshi's type, distal anterior compartment type, or scapuloperoneal type. These phenotypic differences were prominent at the early stages, but were difficult to recognize later in the progression of the disease. Patients with missense mutations had significantly more severe functional status at examination and higher creatine kinase levels than those with frameshift or nonsense mutations.
Conclusion: Dysferlinopathy exhibited marked heterogeneity in the age at onset, initial distribution of muscle involvement, and rate of disease progression. As this heterogeneity was observed even within the same family, some additional factors distinct from dysferlin might be involved.
Comment in
-
Different phenotypes in dysferlinopathy.Intern Med. 2002 Jul;41(7):505-6. doi: 10.2169/internalmedicine.41.505. Intern Med. 2002. PMID: 12132514 No abstract available.
Similar articles
-
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.Arch Neurol. 2007 Aug;64(8):1176-82. doi: 10.1001/archneur.64.8.1176. Arch Neurol. 2007. PMID: 17698709
-
Dysferlinopathy: a clinical and histopathological study of 28 patients from India.Neurol India. 2008 Jul-Sep;56(3):379-85; discussion 386-7. doi: 10.4103/0028-3886.40964. Neurol India. 2008. PMID: 18974568
-
Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations.Neuromuscul Disord. 2001 Jan;11(1):20-6. doi: 10.1016/s0960-8966(00)00157-7. Neuromuscul Disord. 2001. PMID: 11166162
-
Dysferlin and muscular dystrophy.Acta Neurol Belg. 2000 Sep;100(3):142-5. Acta Neurol Belg. 2000. PMID: 11098285 Review.
-
[Dysferlinopathy. Example of a new myopathy].Bull Acad Natl Med. 2002;186(6):1025-32; discussion 1033-4. Bull Acad Natl Med. 2002. PMID: 12587341 Review. French.
Cited by
-
Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B.J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):433-40. doi: 10.1136/jnnp-2011-301339. Epub 2012 Dec 15. J Neurol Neurosurg Psychiatry. 2013. PMID: 23243261 Free PMC article.
-
Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.Int J Mol Sci. 2022 Apr 27;23(9):4824. doi: 10.3390/ijms23094824. Int J Mol Sci. 2022. PMID: 35563214 Free PMC article. Review.
-
A Novel Homozygous Variant in DYSF Gene Is Associated with Autosomal Recessive Limb Girdle Muscular Dystrophy R2/2B.Int J Mol Sci. 2022 Aug 11;23(16):8932. doi: 10.3390/ijms23168932. Int J Mol Sci. 2022. PMID: 36012197 Free PMC article.
-
Heterogeneous characteristics of Korean patients with dysferlinopathy.J Korean Med Sci. 2012 Apr;27(4):423-9. doi: 10.3346/jkms.2012.27.4.423. Epub 2012 Mar 21. J Korean Med Sci. 2012. PMID: 22468107 Free PMC article.
-
Dysferlin Gene Mutation Spectrum in a Large Cohort of Chinese Patients with Dysferlinopathy.Chin Med J (Engl). 2016 Oct 5;129(19):2287-93. doi: 10.4103/0366-6999.190671. Chin Med J (Engl). 2016. PMID: 27647186 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
